O
ver the objections of Doctors Without Borders, the Indian government has awarded a patent to Pfizer (PFE) for its best-selling Prevnar 13 pneumococcal vaccine, a move the advocacy group says will restrict access to many patients for nearly a decade.
In reaching its decision, the Indian Patent Office determined the Pfizer patent was sufficiently unique to merit protection, even though Doctors Without Borders filed paperwork last year arguing otherwise. The patent “does not meet the inventive step requirement [and] it ought to have been rejected,” the advocacy group wrote in a statement after the government decision was announced.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
